P3-239: Clinical Characteristics Of Sarcomatoid Carcinoma Of The Lung  by Lee, Jongmog et al.
Copyright © 2007 by the International Association for the Study of Lung Cancer S781
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
P3-237 NSCLC: Surgery Posters, Wed, Sept 5 – Thur, Sept 6 
Expression characteristics and prognostic significances of MUC1 
and MUC4 in non-small cell lung carcinoma
Kwon, Kun Y.1 Jeon, Ji M.2 Choi, Won I.3 
1 Department of Pathology, Keimyung University School of Medicine, 
Daegu, Korea 2 Department of Pathology, Pocheon Choong-mun 
Colledge of Medicine, Gumi Cha Hospital, Gumi, Korea 3 Keimyung 
University School of Medicine, Daegu, Korea 
MUC1 and MUC4 are high molecular weight membrane-bound gly-
coprotein that can be detected in normal and malignant epithelial cells. 
Their expression has been related to the prognosis of some malignant 
epithelial tumors. However, in lung cancer, little is known about the re-
lationship between the expression of epithelial mucin (MUCs) and clin-
icopathological parameters in non-small cell lung carcinoma (NSCLC). 
In this study, we evaluated the correlation between MUC1 and MUC4 
expression and histologic subtypes. We also investigated the correlation 
between high expression of MUC1 and MUC4 and clinical prognostic 
signiﬁcance in the series. We performed the immunohistochemical 
stains for MUC1 and MUC4 on formalin-ﬁxed, parafﬁn-embedded 
tissue samples from 165 cases of NSCLC arranged in a high-density 
tissue microarray. We found a signiﬁcant correlation between MUC1 
and MUC4 expression and histologic subtypes (p<0.05). High levels 
of expression for MUC1 were more characteristic of adenocarcinoma. 
Low levels of expression for MUC1 and MUC4 were more character-
istic of squamous cell carcinoma. There was a signiﬁcant association 
between increased MUC1 expression (extensiveness 3+) and shortened 
survival (p=0.005). Reversely, the high levels of MUC4 expression 
gave a trend toward longer patient survival (p=0.127). In conclusion, 
MUC1 and MUC4 expression are associated with speciﬁc histologic 
subtypes. There was different prognostic signiﬁcance between MUC1 
and MUC4 in NSCLC.
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Background: The current international TNM staging system has been 
respected as the most important factor for determining patient manage-
ment and estimating the prognosis of NSCLC patients. To estimate the 
appropriateness of the present TNM classiﬁcation, we retrospectively 
analyzed our data of patients with non-small cell lung cancer.
Methods: A retrospective review of 1479 patients with primary lung 
cancer treated at Asan Medical Center from June 1989 through Decem-
ber 2004 was performed. There was a 2.8 % hospital mortality during 
same period and The survival rate was estimated using the Kaplan-Mei-
er method, and the difference in survival was tested by the log-rank test.
Results: There was a 44.6% mortality and a 2.8% hospital mortality 
in our study. The survival rate for 5-year was 60.1% and for 10-year 
43.7%. The 5-year survival rates by pathological stage were as follows: 
76.3% for IA (n=234), 71.3% for IB (n=480), 62.8% for IIA (n=42), 
55.7% for IIB (n=273), 38.3 for IIIA (n=347), 45.3% for IIIB (n=67), 
and 54.6% for IV (n=20). The difference in prognosis between stage 
IIB and IIIA was signiﬁcant (P < .001). There were no signiﬁcant dif-
ference between IA and IB, between IB and IIA, between IIA and IIB, 
between IIIA and IIIB, or between IIIB and IV. The 5-year recurrence-
free survival rates by pathological stage were as follows: 63.6% for IA, 
58.7% for IB, 52.3% for IIA, 48.3% for IIB, 26.5% for IIIA, 40.0% 
for IIIB, and 30.0% for IV. We compared the survival rate of patients 
underwent surgical resection between 1989 and 2000 (early period, 
n=737) and with between 2001 and 2004 (late period, n=742). The 
5-year survival rate of the late period was better than that of the early 
period (64.6% vs 56.3%, P = .002). 
Conclusions: The present TNM staging system seems to characterize 
patient prognosis reliably. The 5-year survival of lung cancer patients in 
the late period was signiﬁcantly improved.
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Background: Carcinomas with sarcoma-like features can occur in the 
lung. These primary non-small cell lung cancers have either a biphasic 
growth pattern with admixtures of carcinoma and sarcomatoid compo-
nents or an exclusively sarcomatoid component with epithelial differen-
tiation demonstrated by immunohistochemistry or electron microscopy 
and have been named as pleomorphic carcinoma, giant cell carcinoma, 
spindle cell carcinoma or carcinosarcoma. Currently “sarcomatoid 
carcinoma” is accepted term for these tumors. It has been reported that 
sarcomatoid carcinoma has a poorer prognosis than other conventional 
non-small cell lung cancers.
Methods: We categorized primary non-small cell lung cancers, which 
had following features as “sarcomatoid carcinoma”: 1) tumors with 
concurrent presence of carcinoma and sarcomatoid components, or 
2) tumors with only sarcomatoid element and positive immunoreac-
tivity for anti-cytokeratin antibody. 937 primary non-small cell lung 
cancers were operated at the National Cancer Center in South Korea 
from 2001 to 2006. Of these, 39 cases were diagnosed as sarcomatoid 
carcinoma and classiﬁed as group A and the others classiﬁed as group 
B. We reviewed the clinicopathologic characteristics of the sarcomatoid 
carcinoma.
Result: There were no statistical differences in sex, age, stage and 
preoperative or postoperative treatment between two groups. 19 cases 
were recurred in sarcomatoid carcinoma group (19/39 48.7 %) and 245 
cases were recurred in the group B (245/898 27.3 %). The group A has 
shorter time to recurrence(107 day vs. 315 p=0.007) and lower 5 year 
disease free survival rate (46.94% vs 59.84% p=0.0037) than group B. 
Also sarcomatoid carcinoma group has lower 5 year survival rate than 
group B(49.95% vs 58.68% p=0.0114). In the Cox proportional hazard 
model, the cell type of sarcomatoid carcinoma is risk factor of lower 
survival rate and lower disease free survival rate.
Conclusion: The sarcomatoid carcinomas of the lung tended show a 
higher recurrence rate and shorter disease free interval than other non-
small cell lung cancers. The effort may be needed to make an accurate 
preoperative diagnosis to apply multimodality treatment to improve the 
prognosis of the sarcomatoid carcinomas.
